share_log

Ladenburg Thalmann Maintains Buy on United Therapeutics, Lowers Price Target to $256

Ladenburg Thalmann Maintains Buy on United Therapeutics, Lowers Price Target to $256

拉登堡塔尔曼维持对United Therapeutics的买入,将目标价下调至256美元
Benzinga ·  2023/05/04 07:45

Ladenburg Thalmann analyst Matthew Kaplan maintains United Therapeutics (NASDAQ:UTHR) with a Buy and lowers the price target from $285 to $256.

拉登堡·塔尔曼分析师马修·卡普兰维持联合治疗公司(纳斯达克:UTHR)的买入,并将目标价从285美元下调至256美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发